Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tularemia | 2 | 2021 | 114 | 1.310 |
Why?
|
| Francisella tularensis | 2 | 2021 | 115 | 1.290 |
Why?
|
| Communicable Diseases, Emerging | 2 | 2018 | 12 | 1.220 |
Why?
|
| Antigen Presentation | 4 | 2015 | 54 | 1.130 |
Why?
|
| T-Lymphocyte Subsets | 5 | 2016 | 88 | 1.090 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2015 | 21 | 1.010 |
Why?
|
| Sepsis | 1 | 2021 | 80 | 0.710 |
Why?
|
| Vaccinia virus | 2 | 2015 | 10 | 0.650 |
Why?
|
| Cytokines | 2 | 2021 | 602 | 0.630 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 3 | 2016 | 16 | 0.580 |
Why?
|
| Lymphocyte Activation | 4 | 2016 | 236 | 0.480 |
Why?
|
| T-Lymphocytes | 3 | 2013 | 357 | 0.470 |
Why?
|
| Peptides | 2 | 2015 | 320 | 0.460 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2013 | 29 | 0.440 |
Why?
|
| Antigen-Presenting Cells | 1 | 2013 | 30 | 0.440 |
Why?
|
| Granzymes | 1 | 2013 | 16 | 0.440 |
Why?
|
| Mycobacterium | 1 | 2013 | 15 | 0.440 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2013 | 42 | 0.440 |
Why?
|
| Isoantigens | 1 | 2010 | 5 | 0.380 |
Why?
|
| Transplantation Tolerance | 1 | 2010 | 3 | 0.380 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2010 | 11 | 0.370 |
Why?
|
| Graft vs Host Disease | 1 | 2010 | 15 | 0.370 |
Why?
|
| Monocytes | 1 | 2013 | 257 | 0.370 |
Why?
|
| Hemiterpenes | 2 | 2016 | 7 | 0.370 |
Why?
|
| Graft Rejection | 1 | 2010 | 38 | 0.360 |
Why?
|
| Graft Survival | 1 | 2010 | 39 | 0.360 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2010 | 55 | 0.360 |
Why?
|
| Organophosphorus Compounds | 2 | 2016 | 37 | 0.360 |
Why?
|
| Obesity | 1 | 2018 | 1067 | 0.350 |
Why?
|
| Leptin | 3 | 2022 | 118 | 0.340 |
Why?
|
| Antigens, Bacterial | 2 | 2016 | 132 | 0.340 |
Why?
|
| Macrophages | 1 | 2013 | 439 | 0.340 |
Why?
|
| Mycobacterium bovis | 1 | 2008 | 15 | 0.330 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2008 | 18 | 0.330 |
Why?
|
| Nicotine | 2 | 2022 | 257 | 0.310 |
Why?
|
| Animals | 11 | 2022 | 15081 | 0.280 |
Why?
|
| Amino Acid Sequence | 3 | 2015 | 1180 | 0.260 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 1609 | 0.260 |
Why?
|
| Molecular Sequence Data | 3 | 2015 | 1568 | 0.260 |
Why?
|
| Tuberculosis | 2 | 2016 | 63 | 0.260 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2016 | 90 | 0.250 |
Why?
|
| Mice | 6 | 2021 | 5913 | 0.250 |
Why?
|
| Proteomics | 2 | 2015 | 325 | 0.200 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2022 | 107 | 0.200 |
Why?
|
| Humans | 13 | 2018 | 37093 | 0.190 |
Why?
|
| Cell Line | 3 | 2015 | 1354 | 0.190 |
Why?
|
| Alginates | 1 | 2020 | 11 | 0.190 |
Why?
|
| Zinc Oxide | 1 | 2020 | 16 | 0.180 |
Why?
|
| Hydrogels | 1 | 2020 | 37 | 0.180 |
Why?
|
| Wound Healing | 1 | 2020 | 70 | 0.170 |
Why?
|
| Lipopolysaccharides | 1 | 2021 | 220 | 0.170 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2019 | 10 | 0.170 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2019 | 26 | 0.170 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2019 | 20 | 0.170 |
Why?
|
| Ventral Tegmental Area | 1 | 2019 | 36 | 0.160 |
Why?
|
| Nucleus Accumbens | 1 | 2019 | 82 | 0.160 |
Why?
|
| Disease Progression | 1 | 2021 | 601 | 0.160 |
Why?
|
| Nicotinic Agonists | 1 | 2019 | 75 | 0.160 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2019 | 94 | 0.150 |
Why?
|
| Exanthema | 1 | 2016 | 10 | 0.140 |
Why?
|
| Dermatomyositis | 1 | 2016 | 7 | 0.140 |
Why?
|
| Insulin | 1 | 2019 | 236 | 0.140 |
Why?
|
| Glycolipids | 1 | 2016 | 9 | 0.140 |
Why?
|
| Antirheumatic Agents | 1 | 2016 | 31 | 0.140 |
Why?
|
| CD40 Ligand | 1 | 2015 | 7 | 0.140 |
Why?
|
| Epitopes | 2 | 2013 | 148 | 0.130 |
Why?
|
| Oncogenes | 1 | 2015 | 43 | 0.130 |
Why?
|
| Nanoparticles | 1 | 2020 | 318 | 0.130 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 1371 | 0.130 |
Why?
|
| Phylogeny | 1 | 2018 | 644 | 0.130 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 149 | 0.120 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2005 | 27 | 0.120 |
Why?
|
| Leucyl Aminopeptidase | 1 | 2013 | 3 | 0.110 |
Why?
|
| Antigens, Ly | 1 | 2013 | 8 | 0.110 |
Why?
|
| Antigens | 1 | 2013 | 56 | 0.110 |
Why?
|
| Structure-Activity Relationship | 3 | 2010 | 409 | 0.110 |
Why?
|
| Sequence Analysis, Protein | 1 | 2013 | 50 | 0.110 |
Why?
|
| Mice, Knockout | 2 | 2013 | 933 | 0.110 |
Why?
|
| Neutralization Tests | 1 | 2013 | 53 | 0.110 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 173 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2013 | 159 | 0.100 |
Why?
|
| Natural Killer T-Cells | 1 | 2011 | 9 | 0.100 |
Why?
|
| Enzyme Inhibitors | 2 | 2005 | 433 | 0.100 |
Why?
|
| Interleukin-15 | 1 | 2011 | 13 | 0.100 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2013 | 149 | 0.100 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2013 | 182 | 0.100 |
Why?
|
| Cell Differentiation | 2 | 2011 | 587 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 1 | 2013 | 186 | 0.100 |
Why?
|
| Peptide Fragments | 1 | 2013 | 308 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 356 | 0.090 |
Why?
|
| Cells, Cultured | 2 | 2013 | 1518 | 0.090 |
Why?
|
| Transplantation, Homologous | 1 | 2010 | 36 | 0.090 |
Why?
|
| Influenza Vaccines | 1 | 2011 | 55 | 0.090 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 409 | 0.090 |
Why?
|
| Th2 Cells | 1 | 2010 | 58 | 0.090 |
Why?
|
| Rats, Wistar | 2 | 2022 | 233 | 0.090 |
Why?
|
| Influenza, Human | 1 | 2011 | 83 | 0.090 |
Why?
|
| Homeostasis | 1 | 2011 | 188 | 0.090 |
Why?
|
| Th1 Cells | 1 | 2010 | 92 | 0.090 |
Why?
|
| Antibodies, Viral | 1 | 2011 | 262 | 0.090 |
Why?
|
| Protein Conformation | 1 | 2010 | 389 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2013 | 517 | 0.080 |
Why?
|
| Ligands | 1 | 2010 | 349 | 0.080 |
Why?
|
| Clone Cells | 1 | 2008 | 47 | 0.080 |
Why?
|
| Immunity, Innate | 1 | 2008 | 149 | 0.080 |
Why?
|
| Models, Molecular | 1 | 2010 | 808 | 0.070 |
Why?
|
| Inflammation | 1 | 2010 | 618 | 0.070 |
Why?
|
| Imidazoles | 1 | 2005 | 126 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2005 | 122 | 0.060 |
Why?
|
| Pyridines | 1 | 2005 | 116 | 0.060 |
Why?
|
| Cell Survival | 2 | 2020 | 864 | 0.060 |
Why?
|
| Cyclin D1 | 1 | 2003 | 43 | 0.060 |
Why?
|
| Rats | 2 | 2022 | 3483 | 0.060 |
Why?
|
| Carbazoles | 1 | 2003 | 42 | 0.050 |
Why?
|
| Corticosterone | 1 | 2022 | 77 | 0.050 |
Why?
|
| Indoles | 1 | 2003 | 158 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 239 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2010 | 1908 | 0.050 |
Why?
|
| Prefrontal Cortex | 1 | 2022 | 137 | 0.050 |
Why?
|
| Female | 2 | 2018 | 20969 | 0.050 |
Why?
|
| Ethanol | 1 | 2022 | 192 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 617 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2011 | 399 | 0.040 |
Why?
|
| Drinking Behavior | 1 | 2019 | 16 | 0.040 |
Why?
|
| Self Administration | 1 | 2019 | 42 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2020 | 272 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2016 | 19 | 0.040 |
Why?
|
| Methotrexate | 1 | 2016 | 23 | 0.040 |
Why?
|
| Methylglucosides | 1 | 2016 | 1 | 0.040 |
Why?
|
| Rheumatology | 1 | 2016 | 16 | 0.040 |
Why?
|
| Consensus | 1 | 2016 | 45 | 0.040 |
Why?
|
| Body Weight | 1 | 2019 | 434 | 0.040 |
Why?
|
| Behavior, Animal | 1 | 2019 | 314 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 27 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 53 | 0.030 |
Why?
|
| Water | 1 | 2019 | 296 | 0.030 |
Why?
|
| Polysaccharides | 1 | 2016 | 58 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 227 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2015 | 38 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2003 | 803 | 0.030 |
Why?
|
| Male | 3 | 2022 | 20025 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2015 | 113 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2019 | 454 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 234 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 259 | 0.030 |
Why?
|
| Immunodominant Epitopes | 1 | 2013 | 27 | 0.030 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2013 | 57 | 0.030 |
Why?
|
| bcl-X Protein | 1 | 2011 | 27 | 0.030 |
Why?
|
| Hela Cells | 1 | 2013 | 366 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2011 | 46 | 0.030 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2011 | 8 | 0.030 |
Why?
|
| Vaccines, Inactivated | 1 | 2011 | 14 | 0.030 |
Why?
|
| Immunization, Secondary | 1 | 2011 | 8 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2013 | 260 | 0.030 |
Why?
|
| Vaccines, Attenuated | 1 | 2011 | 72 | 0.020 |
Why?
|
| Thymus Gland | 1 | 2011 | 81 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2011 | 90 | 0.020 |
Why?
|
| Spleen | 1 | 2011 | 199 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 689 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2010 | 133 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 176 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 93 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2010 | 120 | 0.020 |
Why?
|
| Vaccination | 1 | 2011 | 288 | 0.020 |
Why?
|
| Transfection | 1 | 2010 | 523 | 0.020 |
Why?
|
| Liver | 1 | 2011 | 479 | 0.020 |
Why?
|
| Child | 1 | 2016 | 3131 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 269 | 0.020 |
Why?
|
| Infant | 1 | 2011 | 1046 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2011 | 1418 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2005 | 35 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 83 | 0.020 |
Why?
|
| Lysine | 1 | 2005 | 113 | 0.020 |
Why?
|
| Drug Design | 1 | 2005 | 162 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2003 | 7 | 0.010 |
Why?
|
| G1 Phase | 1 | 2003 | 33 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2003 | 27 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2003 | 113 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 307 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 502 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2003 | 928 | 0.010 |
Why?
|